Huntley's view is...we consider it probable an existing player in the HIV space will bid for AVX sometime in the next year......there are several players who could increase the potency and patent life of their existing HIV portfolios by combining ATC and their compounds. They further comment that an existing player with distribution capability could pay more than $1.50
